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Bovine lactoferrampin (LFampinB) has been identified as a novel antimicrobial peptide, which is derived from the N-terminal lobe of bovine
lactoferrin. In this study, the solution structure of LFampinB bound to negatively charged sodium dodecyl sulphate micelles and zwitterionic
dodecyl phosphocholine micelles was determined using 2-dimensional nuclear magnetic resonance (NMR) spectroscopy. The interaction between
LFampinB and multilamellar phospholipid vesicles, containing choline and glycerol head groups, was examined using differential scanning
calorimetry (DSC). In addition, the interaction between the N-terminal tryptophan residue and model membranes of varying composition was
analyzed by fluorescence spectroscopy. LFampinB adopts an amphipathic alpha-helical conformation across the first 11 residues of the peptide but
remains relatively unstructured at the C-terminus. The hydrophobic surface of the amphipathic helix is bordered by the side chains of Trp1 and
Phe11, and is seen in both micelle-bound structures. The fluorescence results suggest that Trp1 inserts into the membrane at the lipid/water
interface. The phenyl side chain of Phe11 is oriented in the same direction as the indole ring of Trp1, allowing these two residues to serve as
anchors for the lipid bilayer. The DSC results also indicate that LFampinB interacts with glycerol head groups in multilamellar vesicles but has
little effect on acyl chain packing. Our results support a two step model of antimicrobial activity where the initial attraction of LFampinB is
mediated by the cluster of positive charges on the C-terminus followed by the formation of the N-terminal helix which binds to the surface of the
bacterial lipid bilayer.
© 2007 Elsevier B.V. All rights reserved.Keywords: Antimicrobial peptide; Lactoferrampin; Lactoferrin; Nuclear magnetic resonance; Micelle-bound peptide structure; Peptide–membrane interactions1. Introduction
The emergence of antibiotic resistant pathogenic bacteria has
triggered a need to discover novel antimicrobial agents.
Antimicrobial peptides are naturally occurring molecules that
have shown promise as effective antimicrobial agents. Some
antimicrobial peptides are fragments of larger proteins thatAbbreviations: LFampinB, bovine lactoferrampin; NOESY, nuclear Over-
hauser effect spectroscopy; TOCSY, total correlation spectroscopy; DPC,
dodecylphosphocholine; SDS, sodium dodecylsulfate; DSS, 2,2-dimethyl-2-
silapentane-5-sulphonic acid; ePC, egg α-phosphatidylcholine; ePG, egg α-
phosphatidylglycerol; ePE, egg α-phosphatidylethanolamine; PA, phosphatidic
acid; MLV, multilamellar vesicle; LUV, large unilamellar vesicle; Ksv, Stern–
Volmer constant; MIC, minimum inhibitory concentration; MBC, minimum
bactericidal concentration; DPPC, 1,2-dipalmitoyl phosphatidylcholine; DPPG,
1,2-dipalmitoyl phosphatidylglycerol; DSC, differential scanning calorimetry
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doi:10.1016/j.bbamem.2007.04.018display higher activity when proteolytically cleaved from the
parent molecule. Examples of these are lactoferricins which are
cleaved from lactoferrin [1,2] and peptides derived from the
proteolysis of lysozyme [3,4]. Recent research into antimicro-
bial peptides has led to the identification of novel antimicrobial
sequences that are found within proteins that are not naturally
cleaved by proteases.
One novel antimicrobial peptide sequence was recently
discovered in bovine lactoferrin and the resulting synthetic
peptide was termed lactoferrampin [5]. Lactoferrin is an 80 kDa
iron binding protein that has been implicated in numerous
functions ranging from antibacterial activity to stimulation of the
immune system [6]. Most of the activity of lactoferrin has been
attributed to the highly cationic N-terminal region of the protein.
Lactoferricin is an antimicrobial peptide derived from this region
that is released through pepsin hydrolysis of lactoferrin under
acidic conditions [1]. This peptide fragment possesses a wide
variety of biological activities including, antimicrobial, antiviral
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are more potent than the intact lactoferrin protein [7]. Many
synthetic peptides modeled after this sequence have been
examined to determine the mechanism of antimicrobial action
of this peptide [8–10]. Bovine lactoferrampin (LFampinB)
corresponds to residues 268–284 of bovine lactoferrin and is
also found in the cationic N-terminal lobe of lactoferrin [5]. This
fragment was identified as a potential antimicrobial sequence
because it possessedmany attributes characteristic of other known
antimicrobial peptides, such as the presence of a tryptophan
residue and a net cationic charge [11,12]. LFampinB was shown
to have antimicrobial activity against both Gram positive and
Gram negative bacteria as well as Candida albicans [5].
In spite of the increasing number of antimicrobial peptides
that are being identified, the mechanism of action for many of
these peptides remains unclear. The majority of antimicrobial
peptides are believed to act upon the bacterial membrane by
making them leaky, punching holes through them or completely
solubilizing them [13]. An important aspect of determining the
mode of action employed by an antimicrobial peptide is to study
its ability to interact with membranes and to determine the
solution structure of peptides bound to membrane mimetic
micelles. This can provide valuable insight into the distribution
of the charges on the surface of the peptide and allows one to
examine if the structure is amphipathic, a characteristic feature
of many antimicrobial peptides [14]. The solution structure of
these antimicrobial peptides bound to lipid micelles can be
extended to predict the interaction between the peptide and the
membrane surfaces of microbes and lends support to certain
models of the mode of action used to kill bacterial cells. To date
the only structural information available for LFampinB is a
circular dichroism study in which it was found that the
LFampinB has a mixture of helical and disordered regions [15].
Here we present the solution structures of bovine lactoferram-
pin bound to negatively charged sodium dodecyl sulfate (SDS)
micelles and zwitterionic dodecylphosphocholine (DPC)micelles.
Furthermore, we characterize the interaction of the N-terminal Trp
residue with large unilamellar vesicles of varying phospholipid
composition. Additionally, we examine the interaction between
LFampinB and multilamellar vesicles using differential scanning
calorimetry. An amphipathic helical structure with a disordered C-
terminus is seen in the micelle-bound structures of LFampinB
determined by NMR spectroscopy. Our results indicate that
LFampinB interacts with vesicles containing phospholipids with
negatively charged head groups, while this interaction is not
evident in the presence of zwitterionic vesicles.
2. Materials and methods
2.1. Synthesis of peptides and materials used
Bovine lactoferrampin (WKLLSKAQEKFGKNKSR) was purchased from
Anaspec, Inc. (San Jose, CA) and obtained at a purity of N95%. This sequence
of LFampinB corresponds directly to that used in the original experiments
reported for this peptide [5]. Peptide concentrations were determined using a
theoretical extinction coefficient of ε(280) 5500 M−1 cm−1.
All phospholipids were obtained from Avanti Polar Lipids (Alabaster, AL)
except for sodium dodecyl sulphate (SDS) which was obtained from EMDChemicals Inc. (Gibbstown, NJ). The phospholipids used in the preparation of
LUVs were egg α-phosphatidylglycerol (ePG), egg α-phosphatidylethanolamine
(ePE) and egg α-phosphatidylcholine (ePC). Deuterated SDS and DPC used in the
NMR samples were obtained from CDN Isotopes (Pointe-Claire, QC, Canada).
1,2-dipalmitoyl phosphatidylglycerol (DPPG) and 1,2-dipalmitoyl phos-
phatidyl choline (DPPC) were obtained from Avanti Polar lipids as sodium salts
(purityN99%) and were used without further purification.
2.2. Vesicle preparation
Large unilamellar vesicles (LUVs) were prepared according to the protocol
described by Schibli et al. [16]. LUVs were prepared from 1:1 mixtures of ePC:
ePG, ePC:ePE and ePE:ePG lipids. Lipid films were prepared by evaporating the
chloroform solvent from the lipid mixtures under a stream of nitrogen followed by
incubation under a vacuum for 1.5 h. The lipid film was resuspended in Tris buffer
(10 mM Tris, 150 mM NaCl, 1 mM EDTA, pH 7.4) and vortexed. The lipid
suspensions were subjected to five rounds of freezing in liquid nitrogen and
thawing, followed by 15 passes through two 0.1 μm polycarbonate filters
(Nucleopore Filtration Products, Pleasonton , CA) using a mini-extruder apparatus
(Avanti Polar Lipids) at room temperature [17,18]. The concentration of lipid in the
LUV samples was determined using the Ames method [19] which determines the
phosphorus concentration within the sample. The phosphorus concentration in the
buffer was determined and subtracted from the samples containing LUVs.
Multilamellar vesicles used in the DSC experiments were prepared
according to the protocol outlined by Prenner et al. [20]. Stock solutions of
DPPG and DPPC were prepared by dissolving the solid powder in pure
methanol. The LFampinB stock solution was also prepared in methanol. All of
the lipid:peptide ratios were prepared using the stock solutions of lipid and
peptide in methanol and then lipid films were achieved by evaporating the
organic solvent under a stream of nitrogen. The lipid films were then placed
under a vacuum overnight to remove any remaining methanol. Lipid films and
buffer were heated to approximately ten degrees above the phase transition
temperature then the lipid film was hydrated with the heated buffer. Samples
were vortexed to ensure full lipid mixing. All the MLV samples were prepared in
20 mM phosphate buffer, containing 130 mM NaCl at pH 7.4.
2.3. Fluorescence
Fluorescence measurements were performed on a Varian Cary Eclipse
fluorimeter (Varian Inc. Palo Alto, CA.) equipped with a temperature control
unit, set at 20 °C, and a multi-cell sample holder. Emission spectra were obtained
between 300 nm and 500 nm using an excitation wavelength of 280 nm. The slit
width for the excitation light was 10 nm except for the samples containing DPC,
where the emission spectra of the Trp fluorophore was significantly higher and
the slit width was adjusted to 5 nm to accommodate the increase in intensity. The
slit width of the emission settings was maintained at 10 nm throughout all the
experiments. Spectra were collected on a 2-mL sample of 1 μM peptide in Tris
buffer at pH 7.4. In these experiments, the following membrane mimetic
environments were tested: 30 μM ePC:ePG LUVs, 30 μM ePC:ePE LUVs,
30 μM ePE:ePG LUVs, 25 mM SDS and 25 mM DPC.
In addition to measuring the intensity changes and blue shifts in the emission
spectra ofLFampinB, acrylamide quenchingwas performed on all of the peptide/lipid
mixtures to calculate Stern–Volmer constants (Ksv) as previously done [16]. 5 μL
aliquots of a 4.0 M stock acrylamide solution were added to the cuvette containing
peptide and lipid. Emission spectra, as previously described, were collected after each
addition of quencher up to a final acrylamide concentration of 0.1 M.
The Ksv [21] for each combination of LFampinB and lipid was calculated
from the equation:
Fo=F ¼ 1þ KSV½Q
where Fo is the initial fluorescence of the peptide and F is the fluorescence
intensity following the addition of soluble quencher, Q.
2.4. Differential scanning calorimetry
DSC data were collected using aMicrocal high-sensitivity VP-DSC (Microcal.
Norhampton,MA). The total lipid concentration in all of the DSC experiments was
Table 1
Blue shift of tryptophan fluorescence in the presence of different membrane
environments compared to the maximum emission wavelength of LFampinB in
buffer
Membrane environment Blue shift of the maximum
wavelength (nm)
SDS 22
DPC 16
ePC:ePG LUVs 8
ePE:ePG LUVs 8
ePC:ePE LUVs 0
ePC LUVs 0
Fig. 1. Fluorescence emission of LFampinB in buffer (A) and in the presence of
SDS (B) and DPC (C) micelles. Because the emission spectra of LFampinB
bound to DPC micelles was collected using an emission wavelength of 5 nm
compared to 10 nm used in the buffer and the SDS samples, the fluorescence
intensity has been multiplied by a factor of 4.
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of 100:1, 50:1 and 10:1. DPPC and DPPG were chosen as model lipids because of
the 16 carbon fatty acyl chains that comprise a large proportion of the lipids found
in biological membranes. Additionally the choline and glycerol head groups give a
zwitterionic and negatively charged vesicle surface respectively. The 1,2-
dipalmitoyl fatty acids also give well-defined transition peaks in the DSC
thermograms in the temperature range tested. For all of the samples, a heating scan
rate of 10 °C/h was used between 20 °C and 60 °C. All of the data acquisition and
analysis was done using the Microcal Origin Software (version 7.0).
2.5. NMR samples
LFampinB was prepared in a 9:1 mixture of H2O:D2O to a concentration of
2.28 mM and a pH of 3.88. Once spectra were collected, deuterated SDS was
added to this sample to a final concentration of 200 mM at a pH of 4.98. Another
sample of LFampinB in the same ratio of H2O and D2O and 200 mM deuterated
DPC was prepared with a peptide concentration of 1.04 mM and the pH was
adjusted to 3.88. The acidic pH in all the NMR samples ensures a slow exchange
of the amide protons with the aqueous solution. DSS was added as an internal
standard to all the NMR samples to a final concentration of 0.2 mM.
2.6. NMR spectroscopy
Two-dimensional NOESY and TOCSY spectra were recorded at 298 K on a
Bruker Avance 700 MHz spectrometer. NOESY mixing times were 500 ms for
peptide samples in H2O:D2O and 100 ms for micelle bound samples. The mixing
time in the TOCSY experiments was 120 ms. Spectra were obtained with
4096×600 data points in the F2 and F1 dimensions and a sweep width of
8992.806 Hz. Water suppression in the NOESY and TOCSY experiments was
achieved using excitation sculpting [22]. All spectra were zero-filled and
multiplied by a shifted sine-bell curve using the NMRPipe software package [23].
2.7. Structure calculations
Spectra were analyzed using NMRView 5.0.1.4 [24] running on a workstation
using the Redhat 7.1 version of the Linux operating system. All spectra were
referenced to DSS at 0.00 ppm. Proton chemical shifts were assigned according to
Wuthrich [25]. Extended peptide structures were generated by CNS [26] and were
used as a starting model for structure calculations. Dihedral angle restraints were
placed upon all of the backbone angles of the peptide, except for Gly12, to start the
dihedral angles of LFampinB in allowed regions of the Ramachandran plot. The
structures were further refined by taking into account the unambiguous and
ambiguous NOE restraints from the NOESY spectra using the program ARIA
(version 1.2) [27]. In the final ARIA run, 100 structures were generated in the ninth
iteration and the 20 lowest energy structures were kept and analyzed.
3. Results
3.1. Tryptophan fluorescence
Examining the change in fluorescence intensity and the shift
in maximum emission wavelength of LFampinB providesinformation about the environment of the Trp fluorophore at
the N-terminus of the peptide. A blue shift in the tryptophan
fluorescence indicates that the fluorophore has moved into a
hydrophobic environment, in this case the lipid tail region of the
phospholipid bilayer. In addition, an increase in the intensity of
the fluorescence indicates that the environment of the fluor-
ophore has also changed from the peptide in buffer alone and that
more of the energy from the excited state of the Trp side chain
must escape as the emission of a photon as opposed to escaping
through other non-radiative processes as it does in solution. This
provides evidence to support the insertion of the N-terminal
tryptophan residue into the hydrophobic core of the lipid bilayer.
The maximum emission wavelength of LFampinB in
aqueous solution is 358 nm. It is assumed that this is the
environment where the tryptophan residue is the most flexible
and should have the highest emission wavelength. The largest
blue shifts are observed in the presence of SDS and DPC
micelles indicating a significant interaction between the peptide
and the hydrophobic core of the lipids (Table 1). The blue shift in
the presence of SDS micelles is larger than that observed in the
presence of DPC micelles. This could be attributed to a stronger
electrostatic attraction between the positively charged LFam-
pinB peptide and the negatively charged SDS head groups.
When tested with LUVs of various composition, LFampinB
interacted with ePC:ePG and ePE:ePG LUVs and not the ePC:
ePE or ePC LUVs. It should be noted that these fluorescence
experiments are not a direct measurement of peptide binding to
the surface of the LUVs. However, there is a significant blue
shift of the tryptophan fluorescence in the presence of ePG
containing LUVs (Table 1) while there is no blue shift observed
when LFampinB is mixed with zwitterionic LUVs composed of
ePC:ePE or ePC alone (Table 1). These results suggest that
LFampinB interacts with the surface of LUVs and that this
interaction is favored by the presence of a negatively charged
head group on the surface of the vesicle.
The maximum fluorescence intensity of Trp1 in LFampinB
increased dramatically in the presence of DPC micelles, and it is
for this reason that the excitation slit width had to be adjusted to
Fig. 2. Stern–Volmer constants calculated from the acrylamide quenching experiment for LFampinB in various membrane mimetic environments. All experiments
were performed in triplicate.
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(Fig. 1). Conversely, the emission spectra of LFampinB in the
presence of SDS micelles had a lower intensity than the peptide
in buffer (Fig. 1).
Determining the Ksv from the acrylamide quenching
experiment provides more information about the extent to
which the tryptophan is buried into the hydrophobic core of the
lipid bilayer. As the Trp side chain embeds itself in the bilayer, it
becomes less exposed to the surrounding solvent. This makes
the fluorophore less susceptible to the effects of a neutral
soluble quencher, such as acrylamide. A lower Ksv means a
greater degree of protection of the Trp residue and indicates that
the fluorophore is inserted into the hydrophobic core of the
bilayer. Excess LUVand detergent was used to ensure that if an
interaction between LFampinB and the lipid species occurred,
all of the peptide in solution would have been in the lipid bound
conformation and any contribution to the fluorescence from the
free floating peptide would have been limited.Fig. 3. Differential scanning calorimetry heating scans of DPPC (A) and DPPG (B) m
100:1, 50:1 and 10:1 as indicated on each figure. The pretransition region of the theThe Ksv for LFampinB in buffer was found to be
∼45 M−1. In the presence of SDS, DPC, ePC:ePG and ePE:
ePG, the Ksv is approximately half that value (Fig. 2). This
indicates that the side chain of Trp1 has inserted itself into the
lipid bilayer in these four membrane environments. This also
supports the blue shifts observed for this peptide in the
presence of these four lipid environments (Table 1). The Ksv
of LFampinB mixed with ePC:ePE, and ePC LUVs is higher
than the other lipid environments tested (Fig. 2). In fact it is
closer to the values obtained for the free peptide in buffer
indicating that the Trp residue is only weakly interacting with
the LUV surface. The lack of a significant blue shift for
LFampinB in these environments (Table 1) also demonstrates
that the tryptophan residue at the N-terminus of LFampinB is
in an environment similar to the peptide in buffer and that the
peptide does not interact with the zwitterionic LUVs in the
same manner as that observed with the negatively charged
LUVs.ultilamellar vesicles and the effect of adding LFampinB to lipid:peptide ratios of
rmogram for each lipid species is shown as insets.
Fig. 4. NOE connectivities of LFampinB bound to SDS (A) and DPC (B)
micelles. Unambiguous NOEs are represented by solid lines while ambiguous
NOEs are shown as broken lines. Note that the majority of the NOEs
contributing to the formation of a helical structure are found in residues at the N-
terminal part (residues 1–11) of the peptide.
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The DSC thermograms of LFampinB mixed with DPPC and
DPPG MLVs are presented in Fig. 3. Increasing the concentra-Fig. 5. Backbone traces of the 20 lowest energy structures of LFampinB bound to SDS
above however, the hydrophobic amino acids, Trp, Leu, Ala and Phe, are colored gray
charged residue, Glu9, has been colored red. Note that in both structures, the side chain
appears to be a hydrophobic patch. Most of the charged amino acids are found on th
amphipathic structure. These figures were generated using MOLMOL [51] with the setion of LFampinB had no significant effect on the thermogram
of DPPC MLVs. In the pure DPPC MLVs, a pretransition was
observed at about 33.5 °C and main phase transition occurred at
approximately 41 °C. These transitions can be found in all of the
other heating scans at all of the lipid:peptide ratios tested with
very little change in heat capacity or shape of the peak (Fig. 3A).
In the case of pure DPPG MLVs, a pretransition occurs at
approximately 31.5 °C with the main phase transition occurring
at around 40 °C. The addition of LFampinB had a small effect
on the phase behavior of DPPG MLVs. The pretransition at
31.5 °C shifted to lower temperatures with increasing
LFampinB content until it disappears at a lipid:peptide ratio of
10:1 (Fig. 3B inset). Despite this effect on the pretransition, the
main phase transition temperature of DPPG in the presence of
LFampinB remained relatively unchanged (Fig. 3B).
3.3. NMR structures
LFampinB adopts a partial helical structure in the presence of
SDS and DPC micelles at 298 K. Many of the distance restraints
observed in the NOESY spectra of LFampinB in SDS and DPC
are between amino acids in the first 11 residues of the peptide
(Fig. 4). Characteristic (i,i+2; i,i+3; i,i+4) medium range NOEs
for α-helical structures are found from residues 1 to 11. Because
of the large number of NOE contacts in this region, a well-
defined helical structure has been determined which encom-
passes residues 1–11 of LFampinB with the final 6 residues at
the C-terminus remaining relatively unstructured (Fig. 5).(A) and DPC (B) micelles. (C) and (D) are in the same orientation as the figures
; basic amino acids, Lys and Arg, have been colored blue; and the only negatively
s of Trp1 and Phe11 are oriented on the same face of the peptide and border what
e opposite side of this hydrophobic patch and contribute to the formation of an
ts of structures fitted across the first 13 residues of LFampinB.
Table 2
Structural statistics for the NMR structures determined for LFampinB bound to
SDS and DPC micelles
SDS bound DPC bound
No. of distance restraints
Unambiguous NOEs 466 404
Ambiguous NOEs 18 15
Unassigned NOEs 2 2
Total NOEs 484 419
Broad Dihedral 15 15
RMSD from ideal values
Bonds (Å) 2.22×10−3±7.29×10−5 2.66×10−3±1.01×10−4
Angles (degree) 0.401±1.12×10−2 0.369±1.06×10−2
Impropers (degree) 0.253±1.71×10−2 0.190±2.28×10−2
Van der Waals (kcal/mol) 15.01±0.61 10.51±1.66
Non-bonded energies
Electronic (kcal/mol) −437.03 (±49.00) −491.15 (±42.61)
Van der Waals (kcal/mol) −146.16 (±2.29) −138.95 (±4.19)
Ramachandran space (%) a
Most Favored 72.1 76.8
Additionally allowed 27.5 23.2
Generously allowed 0.4 0
Disallowed 0 0
Global RMSD (Å) b
Backbone 0.741 0.577
Heavy 1.358 1.168
a Calculated by PROCHECK [52].
b Calculated by MOLMOL [51] using the first 13 residues of LFampinB from
the 20 lowest energy structures obtained from the ARIA calculations.
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mimetic environment are shown in Table 2. The statistics for the
Ramachandran space and the RMSD are based on the 20 lowestFig. 6. Ribbondiagramof a representative structure ofLFampinBbound toSDS (AandB)
the edges of a hydrophobic patch that also contains Leu3, Leu4 and Ala7. In panel B,
hydrophobic patch or they are found in the unstructured C-terminus. The only negatively ch
surface as possible. The same coloring scheme has been used for the DPC bound structure
was generated using MOLMOL [51].
(energy structures from the ARIA calculations using NOE
distance restraints. The RMSD values have been calculated for
the well-structured helical portion of the peptide and most of the
unstructured C-terminus has not been taken into account for
these values. Many of the backbone dihedral angles are found in
the most favored or additionally allowed regions of the
Ramachandran diagram and none of them are found in
disallowed regions (Table 2).
Fig. 5 shows the backbone traces of LFampinB bound to
micelles as well as charged and hydrophobic residues of the 20
lowest energy structures of the peptide in both lipid environ-
ments. The backbone and heavy atom RMSD for the structurally
defined region of LFampinB, encompassing the first 13 residues,
bound to SDS micelles is 0.741 Å and 1.358 Å, respectively.
Examination of the SDS bound structure of LFampinB reveals a
mostly helical structure between residues 1 and 11 (Fig. 5A). The
cationic C-terminal region containing Lys13, Lys15 and Arg17
remains unstructured especially residues 15 and 17 (Fig. 5C).
Gly12 follows the helix in LFampinB and it seems to initiate the
flexibility of the C-terminal region.
A hydrophobic patch bordered by Trp1 and Phe11 is present
in the SDS bound structure of LFampinB with the side chains of
these aromatic residues both oriented in the same direction
(Fig. 6A). Leu3, Leu4 and Ala7 are the other residues found in
this region and they contribute to the hydrophobicity of this
patch. The helical portion of LFampinB bound to SDS displays
an amphipathic structure due to the charged face that lies op-
posite the hydrophobic patch. The positively charged residues
in the helical region, namely Lys2, Lys6 and Lys10 are all
oriented away from the hydrophobic patch (Fig. 6B). The only
negatively charged residue in LFampinB is Glu9 whose charged
side chain is oriented in the same direction as the positively
charged Lys6 residue and could indicate a favorable ion-pairandDPC (CandD). In panelA,Trp1 andPhe11 are highlighted in green and they form
the positively charged amino acids are shown in blue and are located opposite the
arged amino acid, Glu9, is colored red and is found as far away from the hydrophobic
with the hydrophobic residues (C) and the charged residues (D) indicated. This figure
Fig. 7. Charge distribution on the surface of LFampinB bound to SDS (A and B) and DPC (C and D) micelles. Positively charged areas are shown in blue and the
negatively charged residue, Glu9, is shown in red. In A and C the hydrophobic patch involving Trp1 and Phe11 is oriented toward the reader with Trp1 on the right
hand side of each structure. B and D show the opposite face of the peptide and help to illustrate the amphipathic nature of LFampinB bound to micelles. These figures
were generated using MOLMOL [51].
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(Fig. 6B).
The backbone and heavy atom RMSD for the DPC bound
LFampinB structure are 0.577Å and 1.168Å respectively across
the first 13 residues. We once again see good agreement between
the NMR structures at the N-terminal portion of the peptide with
the C-terminal residues being more disordered (Fig. 5B). Similar
to the SDS bound structure, the hydrophobic amino acids orient
themselves on one face of the peptide and positively charged
residues are found opposite to this hydrophobic surface or in the
unstructured C-terminus (Fig. 5D).
Upon closer examination of the structure of LFampinB
bound to DPC, we see once again the formation of a helix
across the first 11 residues of the peptide (Fig. 6C and D). Trp1
and Phe11 are found at the edges of a hydrophobic patch
similar to that observed in the SDS bound structure (Fig. 6C).
The Trp1 side chain appears to remain closer to the helix axis
in the DPC bound structure compared to the SDS boundFig. 8. Schematic representation of the interactions between magainin (A), tritrpticin
colored gray. Positively charged residues are shown in blue and negatively charged re
and the hydrophobic core are colored dark and light gray respectively. This figure wasstructure (Fig. 6C). The charged amino acid side chains are
also found on the opposing face of this hydrophobic patch
except for Lys10 which is found perpendicular to the
hydrophobic patch (Fig. 6D).
4. Discussion
Determining the structure of an antimicrobial peptide can
potentially provide insight into the mechanism used by the
molecule to exert its antimicrobial effect. The predicted
secondary structure of LFampinB indicates that the C-terminal
residues of the peptide might be a random coil and examination
of the corresponding stretch in the crystal structure of the intact
bovine lactoferrin protein indicates that the C-terminal residues
of LFampinB do not have regular secondary structure while the
N-terminal residues form an α-helix [28]. A circular dichroism
study of LFampinB suggested that the peptide contained both
helical and flexible regions [15], however CD spectra cannot(B) and LFampinB (C) and a lipid bilayer. Hydrophobic side chains have been
sidues are in red. The lipid bilayer is shown in the background. The head groups
generated usingMOLMOL [51].
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structures of LFampinB bound to micelles presented here
clearly show a flexible C-terminal region of the peptide with a
well-defined N-terminal helix stretching from residues 1–11.
Both structures presented for LFampinB have a patch of
hydrophobic residues on one face of the peptide (Fig. 5). The
charged amino acid side chains are for the most part found
opposite to this hydrophobic patch which gives lactoferrampin
an amphipathic structure characteristic of other antimicrobial
peptides derived from lactoferrin [2,29] and other sources [30].
However, a glycine scan of a slightly longer form of LFampinB,
LFampin 265–284, has revealed the importance of the
positively charged residues in the antimicrobial activity of
LFampinB [31]. Substitution of five of the six positively
charged residues in LFampinB led to a significant decrease in
the antifungal activity of LFampin 265–284. The corresponding
residues in LFampinB are Lys6, Lys10, Lys13, Lys15 and
Arg17 and they all reside closer to the flexible end of
LFampinB. The mutation of the residue corresponding to
Lys2 in LFampinB to a glycine only had a minor effect on the
antimicrobial activity of the peptide.
The importance of the cationic nature of antimicrobial
peptides has been well documented [32,33]. It appears that
LFampinB is capable of interacting with negatively charged
membranes. The strongest fluorescence blue shift was observed
in LUVs containing the negatively charged phosphatidylgly-
cerol. This interaction could be due to the cationic charge of
LFampinB which is favorably attracted to the negatively
charged head groups of the ePG molecules. Many of the
studies of LFampinB have focused on the candidacidal activity
of this peptide [15,31,34]. The plasma membrane of Candida
species contains a large proportion of negatively charged
phospholipids, namely phosphatidic acid (PA) and phosphati-
dylglycerol [35]. In fact, the small head group on a PA molecule
is similar to the small negatively charged head group of SDS,
which also demonstrated a large blue shift in the fluorescence
experiments. This could translate to a similar interaction
between Candida plasma membranes and LFampinB. The
decrease in fluorescence intensity observed when LFampinB
interacted with SDS micelles is counter intuitive because if the
tryptophan residue is binding to the micelle, there should be an
increase in the intensity observed in the emission spectra. We
have attributed the quenching of the tryptophan fluorescence in
the presence of the SDS micelles to an interaction with the head
groups of the detergent molecules. Our group has previously
reported significant quenching of Trp fluorescence by sulfur
atoms in methionine residues [36] and this might help explain
the observed results because of the sulfur atom in the head
group of the SDS molecules. However, the quenching of Trp
fluorescence can involve many different pathways and
mechanisms and we cannot be certain that this is the only
factor contributing to the quenching of the emission from
LFampinB in the presence of SDS.
Interestingly there is no significant blue shift in the presence
of LUVs made from ePE:ePC or pure ePC. The lack of a blue
shift in the presence of these zwitterionic phospholipids is
understandable if electrostatic interactions mediate the initialbinding of the peptide to the bilayer. The negative charges on
the head groups of PG and SDS molecules could attract the
positively charged LFampinB peptide followed by binding of
Trp1 to the hydrophobic core of the membrane. In the case of
the zwitterionic DPC micelles, it appears that Trp1 is capable of
inserting into the hydrophobic core of the micelle despite the
lack of an overall net negative charge to attract the positively
charged peptide. This is attributed to a higher detergent
concentration in the DPC micelles compared to the phospho-
lipid concentration in the LUV samples, consequently pushing
the equilibrium of LFampinB in the mixture to the membrane
bound conformation. This is supported by the well-resolved
NMR spectra that were acquired for LFampinB bound to DPC
micelles, which allowed for the calculation of a well-defined
peptide structure.
DSC has proven to be a valuable tool in examining
interactions between antimicrobial peptides and lipids [37].
The DSC results support an electrostatic interaction between
LFampinB and negatively charged phospholipids. The conver-
sion from the lamellar gel phase to a rippled gel phase is what
gives rise to the pretransition observed in DSC scans of lipid
suspensions. This pretransition is due to interactions between
the head groups of the lipid molecules and increasing the
distance between the head groups through the insertion of a
peptide eliminates these interactions and causes the pretransi-
tion peak to disappear [38]. The pretransition in DPPG bilayers
disappears at high lipid:peptide ratios, indicating that LFam-
pinB disrupts the head group organization in negatively charged
DPPG MLVs. The main phase transition represents the
conversion from the gel phase to a liquid crystal phase and is
strongly influenced by the acyl chain packing of the
phospholipid molecules [38]. Since there is no significant
change in the main phase transition peak, it can be assumed that
LFampinB does not significantly disrupt the acyl chain packing
of the DPPGMLVs. There were no significant differences in the
pretransition or the main phase transition of DPPC MLVs at
various concentrations of LFampinB, indicating that the
interactions between the peptide and membranes is head
group dependant. The disappearance of the pretransition in
DPPG MLVs has been observed for a 15-residue antimicrobial
peptide derived from bovine lactoferricin with very little effect
on the main phase transition. These peptides also demonstrated
no effect on DPPC MLVs [39].
Tryptophan residues have the unique ability to reside at the
lipid water interface of a plasma membrane [40] and their
importance in antimicrobial peptides is well documented [11,13].
Many antimicrobial peptides contain one or more tryptophan
residues and often they are key residues for determining activity
[41]. Along with Phe11, Trp1 is found at the edge of a
hydrophobic patch in LFampinB (Fig. 6A). The tryptophan
fluorescence results demonstrate that the side chain of Trp1
becomes protected from the effects of a soluble quencher in the
presence of a lipid micelle and vesicles with acidic head groups
(Fig. 2) indicating that this residue preferentially inserts into the
bilayer. Phenylalanine is a hydrophobic amino acid that is known
to serve as a membrane anchor in transmembrane helices [42] as
well as anchoring other antimicrobial peptides to the surface of a
2363E.F. Haney et al. / Biochimica et Biophysica Acta 1768 (2007) 2355–2364plasmamembrane [43]. The hydrophobic side chain of Phe11 side
chain likely inserts into the hydrophobic core of the membrane
and both of these residues serve to anchor LFampinB to the
plasma membrane. This argument is more compelling consider-
ing that substitution of Trp1 with a glycine residue in LFampinB
resulted in lower killing activity of the peptide [31] implying that
this mutant was unable to bind to the surface of a plasma
membrane.
The amphipathic nature of LFampinB is easily observed
when the distribution of charges over the surface of the peptide
is examined. The hydrophobic patch found in both the SDS-
bound (Fig. 7A) and DPC-bound (Fig. 7C) structures of
LFampinB is clearly visible. The opposite face of the
hydrophobic surface contains most of the charged residues. It
is also important to highlight the proximity of the negatively
charged Glu9 to the nearby positively charged Lys6 in the SDS
bound form of LFampinB (Fig. 7B). The repulsion effects
between the acidic glutamate residue and the negatively charged
bacterial membrane are mitigated by the proximity to the
positively charged lysine residue and allow for the interaction of
the hydrophobic patch with the membrane. In the DPC-bound
structure, the negative charge from the glutamate side chain
appears to be further away from any of the surrounding positive
charges (Fig. 7D) likely because the charge repulsion between
the peptide and the lipid is weaker in the presence of the
zwitterionic micelle.
LFampinB and the longer form, LFampin 265–284, appear
to act like a detergent and solubilize the plasma membrane of
yeast and bacterial cells. Treatment of C. albicans and E. coli
cells with LFampinB and LFampin 265–284 had large effects
on plasma membrane integrity ranging from the formation of
blebs to the appearance of vesicle like structures [34]. This has
been described as the carpet model of membrane disruption as a
mechanism of antimicrobial activity [44]. The amphipathic
structure determined in this study lends support to this model of
antimicrobial activity as do the tryptophan fluorescence and
DSC studies. Once an effective concentration of LFampinB is
reached, the hydrophobic patch on LFampinB inserts into the
lipid bilayer and causes the plasma membrane to break apart
leading to cell death.
It is useful to compare the micelle-bound structure of
LFampinB to structures of other antimicrobial peptides. Magai-
nin, the first linear antimicrobial peptide discovered from the skin
of the African clawed frog [45] is relatively unstructured in
aqueous solution. In the presence of lipids, magainin adopts a
right-handed α-helical conformation that is amphipathic in nature
[46,47]. The hydrophobic face of magainin preferentially inserts
into the hydrophobic core of the lipid membranes and the posi-
tively charged face of the helix interacts with the negative head
groups of the phospholipid bilayer (Fig. 8A). The amphipathic
helix is a common motif observed in many other antimicrobial
peptides [48] and the parallel orientation to the lipid bilayer
normal has been found in other mammalian antimicrobial
peptides. The human antimicrobial peptide LL-37 has been
shown to reside in the interfacial region of a plasma membrane
with the charged surface of the peptide interacting with the
charged head groups of the lipids and the hydrophobic residuesanchoring the peptide into the hydrophobic core of the bilayer
[49]. The structures of LFampinB presented here represent a
novel structural feature for helical antimicrobial peptides where
the positively charged residues that are most important for the
antimicrobial activity are flexible when bound to the membrane
mimetic (Fig. 8C). Flexibility in the positively charged residues of
an antimicrobial peptide has also been observed in tritrpticin
where the arginine residues located at the N- and C-terminus of
the peptide remain relatively unstructured while most of the non-
polar residues contribute to the formation of a hydrophobic turn–
turn structure that is thought to wedge into the center of the
membrane [50] (Fig. 8B). However, most of the solution
structures of helical amphipathic antimicrobial peptides reported
to date demonstrate awell structured charged region of the peptide
overlapping with the ordered hydrophobic portion of the peptide.
The structures of LFampinB indicate that the positively charged
residues at the C-terminus are required for its initial attraction to
the negatively charged bacterial membrane surface but once the
peptide binds, these residues do not appear to be directly involved
in peptide binding to the membrane. This task is then taken over
by the amphipathic helical portion of the peptide.Acknowledgements
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